Every Form 4 that Elicio Therapeutics, Inc. (ELTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTX filings page.
Elicio Therapeutics, Inc. (ELTX) reported that director Julian Adams received a stock option grant for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.
The award is the annual non-employee director equity grant and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to his continued service. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Carol Gail Ashe received a grant of stock options for 21,750 shares of common stock on August 31, 2026. The options have an exercise price of $2.70 per share and expire on August 31, 2036. They represent the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders meeting, subject to continued service.
Elicio Therapeutics, Inc. (ELTX) reported that director and ten percent owner Yekaterina Chudnovsky received a grant of stock options for 21,750 shares of common stock on August 31, 2026, at an exercise price of $2.70 per share, held as a direct derivative position.
The options represent her annual non-employee director equity award and will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Allen Nissenson received a stock option award for 21,750 shares of common stock on August 31, 2026. The option has an exercise price of $2.70 per share and expires on August 31, 2036.
The option represents the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027, or the company’s 2027 annual meeting of stockholders, provided he continues to provide services through the vesting date. No additional equity award will be made to him in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Robert R. Ruffolo received a grant of 21,750 stock options on August 31, 2026 as his annual non-employee director equity award. The options have an exercise price of $2.70 per share, cover 21,750 shares of common stock, and expire on August 31, 2036. They vest and become exercisable in full on the earlier of August 31, 2027 or the 2027 annual stockholder meeting, subject to his continued service, and no additional equity award will be made to him in connection with the 2026 annual meeting.
Elicio Therapeutics, Inc. (ELTX) reported that director Karen J. Wilson received a grant of 21,750 stock options on August 31, 2026 as an annual non-employee director equity award. The options have an exercise price of $2.70 per share, expire on August 31, 2036, and cover 21,750 shares of common stock.
The award will vest and become exercisable in full on the earlier of August 31, 2027 or the company’s 2027 annual stockholders’ meeting, subject to her continued service. No additional equity award will be made to her in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 plan is reported.
Elicio Therapeutics, Inc. (ELTX) reported that director Jay Venkatesan received a grant of stock options for 21,750 shares of common stock on August 31, 2026 at an exercise price of $2.70 per share. The options vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders’ meeting, subject to continued service, and expire on August 31, 2036. No additional equity award will be made to this director in connection with the 2026 annual meeting of stockholders, and no Rule 10b5-1 trading plan is reported.
Elicio Therapeutics, Inc. reported that Executive Vice President, Head of R&D and Chief Medical Officer Christopher Haqq received a grant of 64,643 stock options on July 16, 2026 at an exercise price of $3.20 per share, expiring on July 16, 2036. The options vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, and cover 64,643 shares of common stock.
Elicio Therapeutics, Inc. reported that Chief Scientific Officer Peter DeMuth received a grant of stock options covering 52,832 shares of common stock. The options have an exercise price of 3.2000 per share and expire on 2036-07-16. They vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, leaving him with 52,832 options outstanding after this grant.
Elicio Therapeutics, Inc. reported that Chief Strategy and Financial Officer Preetam Shah received a grant of stock options covering 60,833 shares of common stock at an exercise price of $3.20 per share. The options expire on July 16, 2036 and vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service.
Elicio Therapeutics, Inc. granted CEO, President and Director Robert Connelly a stock option for 186,944 shares of common stock at an exercise price of 3.2000 per share on July 16, 2026, expiring July 16, 2036. The option vests 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, resulting in direct holdings of 186,944 options under this award.
Elicio Therapeutics CEO Robert Connelly received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 73,600 restricted stock units of common stock at a price of $0, increasing his directly held common shares to 120,570.
He was also granted 147,200 stock options with an exercise price of $8.10 per share, all held directly. Both the RSUs and options vest 25% on February 2, 2027, with the remaining portions vesting over the following three years, contingent on his continued service to the company.
Elicio Therapeutics granted equity awards to its Chief Strategy and Financial Officer, Preetam Shah, on February 2, 2026. He received 24,000 restricted stock units, each representing one share of common stock at no cost on grant, and 47,900 stock options to buy common shares at an exercise price of $8.10 per share.
The RSUs vest 25% on February 2, 2027, with the rest vesting in annual installments over the following three years, contingent on continued service. The options vest 25% on February 2, 2027, with the remainder vesting in monthly installments over three years thereafter, also subject to continued service.
Elicio Therapeutics granted equity awards to its Chief Scientific Officer, Peter DeMuth. He received 20,800 restricted stock units at a price of $0 and now beneficially owns 21,543 common shares directly. The RSUs vest 25% on February 2, 2027, then annually over three more years, conditioned on continued service.
DeMuth also received a stock option for 41,600 shares of common stock with an exercise price of $8.10 per share. The option vests 25% on February 2, 2027, with the remaining portion vesting monthly over three years, also subject to his continued service.
Elicio Therapeutics, Inc. granted equity awards to executive Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer. On February 2, 2026, he received 25,400 restricted stock units (RSUs) of common stock at $0 cost and a stock option for 50,900 shares with an exercise price of $8.1 per share.
The 25,400 RSUs vest 25% on February 2, 2027, then annually over three additional years, contingent on continued service. The 50,900 options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years. After these grants, he directly holds 57,381 common shares and 50,900 options.